Representatives of generic producers are pressing to be able to use the name of the active principle relating to the 'designer' originals for bioequivalent medicines. At the moment, in fact, not being able to use the same Inn (International Non-proprietary Name), or common name (for example simvastatin for Zocor*), identical to the original, puts the potential sales of bioequivalent drugs at risk. Speaking at the symposium of the European Generic Medicines Association (EGA), Sozette Kox, scientific director of the EGA, examined the issue, arguing that in Europe it would be up to the experts of the drug agency to decide whether or not a bioequivalent medicinal product can bear the name of the original product. http://www.egagenerics.com/
